Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05539430 · ClinicalTrials.gov registry record · Phase 1
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
A Phase 1 study of Pancreatic Cancer and Gastric Cancer, sponsored by Legend Biotech USA.
- Active
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 9
- Study locations
NCT05539430 is a Phase 1 study of Pancreatic Cancer and Gastric Cancer that is active but no longer recruiting, run by Legend Biotech USA. The registered enrollment target is 56 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (86% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT05539430, a Phase 1 study of Pancreatic Cancer and Gastric Cancer, is active but no longer recruiting, sponsored by Legend Biotech USA.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Conditions Studied
Interventions
- BIOLOGICAL LB1908
Study Locations (9)
Florida
- Moffitt Cancer Center - Tampa
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- John Theurer Cancer Center at HackensackUMC - Hackensack
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
North Carolina
- Duke University - Durham
Oregon
- OHSU Knight Cancer Institute - Portland
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05539430
The ClinicalTrials.gov registry entry for NCT05539430 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Legend Biotech USA, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which LB1908 is the first listed.
NCT05539430 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Florida, Michigan, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05539430 about?
NCT05539430 is a clinical study titled "Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma". This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
What is the current status of trial NCT05539430?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-04-18. Estimated completion is 2027-12.
What conditions does trial NCT05539430 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT05539430?
The interventions under investigation include: LB1908 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05539430?
This trial is sponsored by Legend Biotech USA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05539430 being conducted?
This trial has 9 study locations across Florida, Michigan, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.